[{"id":"e8a0c5a3-854f-4878-82dd-a53e0b5e2e5b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05698199","created_at":"2023-11-22T19:16:45.757Z","updated_at":"2024-07-02T16:35:12.688Z","phase":"Phase 1","brief_title":"Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM)","source_id_and_acronym":"NCT05698199","lead_sponsor":"Immunomic Therapeutics, Inc.","biomarkers":" CD8 • CD163 • FOXP3","pipe":"","alterations":" ","tags":["CD8 • CD163 • FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ITI-1001"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/21/2023","start_date":" 08/21/2023","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-03-26"}]